Print…

You Searched For: uPA+Inhibitor+II


35,853  results were found

Refine Results Sort by
SearchResultCount:"35853"

Sort Results

List View Easy View

Rate These Search Results

Image Unavailable-AAJ64874-MB

uPA Inhibitor II, solid

Supplier: Thermo Scientific Chemicals
Description: A cell-permeable oxazolidinone-carboxamidine compound that acts as a potent, selective, and active-site targeting inhibitor of urokinase-type plasminogen activator

SDS Certificates

Image Unavailable-102987-202

(-)-Epigallocatechin Gallate ≥98% (by HPLC)

Supplier: Adipogen
Description: Potent anticancer compound. Anti-angiogenic. VEGF, VE-cadherin phosphorylation, matrix metalloproteinase and urokinase-plasminogen activator (uPA) inhibitor. Anti-inflammatory. NF-kappaB inhibitor. Modulates chronic inflammatory diseases, such as type 2 diabetes, rheumatoid arthritis, inflammatory bowel disease. COX-2 and inducible nitric oxide synthase (iNOS; NOS II) inhibitor. Potent antioxidant. Protects cells from lipid peroxidation and DNA damage induced by reactive free radicals. Regulates cancer cell growth, proliferation, transformation, survival, angiogenesis, apoptosis, invasion and metastasis. Chemopreventive. Apoptosis inducer. Promotes cell cycle arrest. Modulates signal transduction pathways including JAK/STAT, MAPK, PI3K/AKT, Wnt and Notch. EGFR and HER-2 receptor signaling inhibitor. MAPKs and activator protein-1 inhibitor. mTOR suppressor. IGF-I signaling inhibitor. Proteasome inhibitor. Telomerase and DNA methyltransferase inhibitor. Selective and noncompetitive HAT inhibitor. Topoisomerase I and II inhibitor. Hedgehog signaling (Hh) modulator. PTCH and Gli1 inhibitor. Wnt signaling inhibitor. Neuroprotective. Activates HO-1 by the ARE/Nrf2 pathway, protecting neurons against oxidative damage. STAT-1 inhibitor. Shows preventive cardiovascular and metabolic (obesity, insulin resistance, hypertension and hypercholesterolemia) effects. Inhibits extracellular signal-related kinases (ERK), activates AMP-activated protein kinase (AMPK), modulates adipocyte marker proteins and down-regulates lipogenic enzymes as well as other potential targets. Fatty acid synthase (FAS) inhibitor. Autophagy stimulator.

Image Unavailable-80056-266

Calbiochem® 1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone, DiHCl

Catalog Number: (80056-266)
Supplier: MilliporeSigma
Description: Effective irreversible inhibitor of uPA, Factor Xa, and urokinase

SDS Certificates


Image Unavailable-10072-644

Human Recombinant PAI2 (from E. coli)

Catalog Number: (10072-644)
Supplier: Prosci
Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa nonglycosylated intracellular protein which can be induced to be secreted as 60 kDa glycoprotein. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/mL), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant human PAI-2 is a 415-residue nonglycosylated protein.
Product Image-10798-350

Human Recombinant Serpin E2 (from HEK293 Cells)

Catalog Number: (10798-350)
Supplier: Prosci
Description: SERPINE2 is also known as Glia-derived nexin (GDN), Peptidase inhibitor 7 (PI7), Protease nexin 1(PN1). SERPINE2 is a secreted glycoprotein which belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). PAI-1 / GDN is also implicated in adipose tissue development. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis. Defects in Serpin E1 / PN1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma.
Image Unavailable-103486-478

Anti-Plasminogen Activator Inhibitor 1 Sheep Polyclonal Antibody

Catalog Number: (103486-478)
Supplier: Affymetrix, Inc.
Description: This Antibody detects Plasminogen Activator Inhibitor 1. It has been successfully used in ELISA applications. The Immunogen is Recombinant PAI-1. This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Blocked
Image Unavailable-103487-320

Anti-SERPINE1 Goat Polyclonal Antibody

Catalog Number: (103487-320)
Supplier: Affymetrix, Inc.
Description: This antibody is predicted to react with canine based on sequence homology. This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Blocked
Image Unavailable-ALA131615-1G

Amiloride hydrochloride ≥98%

Supplier: ALADDIN SCIENTIFIC CORPORATION
Description: Amiloride ? HCl is a selective T-type calcium channel protein inhibitor that has been shown to inhibit the Polycystin-L channel (Polycystic kidney disease 2-like 1 protein: PKD2L1), a member of the transient receptor potential (TRP) superfamily of cation channels, including the NHE (sodium/hydgrogen exchanger). Amiloride is also an epithelial sodium channel protein inhibitor, which inhibits sodium reabsorption without affecting potassium concentrations. Amiloride serves as a non-selective acid-sensing ion channel (ASIC) blocker and a selective inhibitor of uPA (urokinase plasminogen activator). Research shows that amiloride reduces electrical potential across tubular epithelium, inhibits angiogenesis and inhibits capillary morphogenesis completely and reversibly at approximately 130 μM. Amiloride ? HCl is an inhibitor of Sodium/Potassium-ATPase Protein.A calcium channel andsodium channel protein inhibitor

New Product

Image Unavailable-10779-400

Human Recombinant PAI-2 (from E. coli)

Supplier: Peprotech
Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa, nonglycosylated, intracellular protein, which can be induced to be secreted as 60 kDa glycoprotein. The glycosylated and unglycosylated forms of PAI-2 are equally effective as inhibitors of urokinase-type plasminogen activator (uPA), the only established physiological target of this serpin. PAI-2 has a unique ability to form dormant polymers spontaneously and reversibly under physiological conditions. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular, dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy, and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant Human PAI-2 is a 46.5 kDa, nonglycosylated protein of 415 residues.

Image Unavailable-103480-148

Anti-PAI Mouse Monoclonal Antibody [clone: I-1]

Catalog Number: (103480-148)
Supplier: Affymetrix, Inc.
Description: MON I-1-02 is specific for human PAI-1. No cross-reactivity is observed with PAI-2 as tested by ELISA and immunoblotting. No reactivity is observed with any other human plasma protein when tested by immunoblotting. MON I-1-02 has successfully been used in ELISA, immunoblotting and immunohistochemistry applications. The immunogen used to produce MON I-1-02 is partially purified human PAI-1. NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/ml Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA). It belongs to the group of serpins (serine protease inhibitors). Elevated levels of PAI-1 are associated with poor prognosis in many types of cancer.

Blocked
Product Image-76012-336

Anti-SERPINE1 Rabbit Polyclonal Antibody

Catalog Number: (76012-336)
Supplier: Prosci
Description: This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Image Unavailable-103467-934

Anti-SERPINE1 Mouse Monoclonal Antibody [clone: MA-33H1F7]

Catalog Number: (103467-934)
Supplier: Affymetrix, Inc.
Description: MA1-40224 detects PAI-1 from human, rat, mouse and rabbit samples. MA1-40224 has been successfully used in ELISA, functional studies, immunohistochemistry (frozen) and Western blot applications. The MA1-40224 immunogen is human PAI-1. PAI (plasminogen activator inhibitor) belongs to serine protease inhibitor superfamily, and is the principal inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA). Platelets are the main source of the circulating PAI-1, but it is synthesized and secreted by many tissue and cell types, including fibroblasts, smooth muscle cells, endothelial cells, hepatocytes, and inflammatory cells. Expression of PAI-1 can be regulated at the transcriptional level by many factors including growth factors, cytokines, hormones, inflammatory factors, glucose or lipid metabolites, vascular tone regulating factors, chemicals, and other environmental or physical factors.

Blocked
Product Image-89161-682

Gabexate mesylate ≥98% (by HPLC)

Supplier: Enzo Life Sciences
Description: A competitive, reversible inhibitor of serine proteases tryptase (Ki=3.4nM), thrombin (Ki=500nM), uPA (Ki=1.3µM), plasmin (Ki=1.5µM), trypsin (Ki=2µM), factor Xa (Ki=2µM). At higher concentrations it inhibits kallikrein-1 (Ki=2.6mM), C1 esterase (IC50=520µM), as well as phospholipase A2 (IC50=500µM), rat iNOS (Ki=5mM) and cNOS (Ki=150µM), and swine kidney copper amine oxidase (Ki=27µM), but not chymotrypsin. Has been used in tissue culture and in vivo. In clinical use for pancreatitis.

Image Unavailable-75789-646

Human Recombinant Serpin A5 (from Cells)

Catalog Number: (75789-646)
Supplier: Prosci
Description: Serpin A5 is a member of the human Serpin superfamily consists of at least 35 members. It is synthesized in the liver and has been detected in saliva, cerebral spinal fluid, amniotic fluid, tears and semen. As a potent inhibitor of the protein C anticoagulant pathway at the levels of both zymogen activation and enzyme inhibition, Serpin A5 additionally inhibits a variety of serine protease including thrombin, factor Xa, several kallekreins and acrosin. It plays a critical role in the processes of blood of blood coagulation and fertilization. Serpin A5 also inhibits urinary plasminogen activator (uPA), a mediator of tumor cell invasion, and regulates tumor growth and metastasis by inhibiting angiogenesis. Furthermore, recent studies have identified PCI as a potent and direct inhibitor of activated HGFA (hepatocyte growth factor activator), suggesting a novel function in the regulation of tissue repair and regeneration. Similar to Serpins C1 and D1, the thrombin inhibitory activity of serpinA5 is enhanced by heparin.
Image Unavailable-103480-150

Anti-PAI Mouse Monoclonal Antibody [clone: I-6]

Catalog Number: (103480-150)
Supplier: Affymetrix, Inc.
Description: MON I-6-02 is specific for human PAI-1. No cross-reactivity is observed with PAI-2 as tested by ELISA and immunoblotting. No reactivity is observed with any other human plasma protein when tested by immunoblotting. MON I-6-02 has successfully been used in ELISA, Western blot and immunohistochemistry applications. The immunogen used to produce MON I-6-02 is partially purified human PAI-1. NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/ml Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA). It belongs to the group of serpins (serine protease inhibitors). Elevated levels of PAI-1 are associated with poor prognosis in many types of cancer.

Blocked
Product Image-101737-096

PAI-1 (Human) AlphaLISA Detection Kits, PerkinElmer

Supplier: Revvity Health Sciences
Description: Formats: 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µl reaction volume (5 µl of sample). 5000 assay point kit allows you to run 5000 wells in 96-well or 384-well format, using a 50 µl reaction volume (5 µl of sample). Features: no-wash steps, no separation steps, ELISA alternative technology, sensitive detection, broad sample compatibility, small sample volume, results in less than 3 hours, half the time of an ELISA assay. Plasminogen activator inhibitor-1 (PAI-1) is a single chain glycoprotein of 50 kDa. PAI-1 is secreted and is mainly produced by the endothelium, liver, and adipose tissue. It is also produced by certain tumours. PAI-1 activity is tightly regulated on the transcriptional level by transforming growth factor ß. PAI-1 is the principal inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA), which convert plasminogen to plasmin. Congenital PAI-1 deficiency can cause hemorrhagic diathesis. PAI-1 is present in larger amounts in various pathologies, such as in a number of cancers or obesity. In breast cancer, high levels of PAI-1 are associated with a high risk of recurrence. AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated donor beads while another anti-analyte antibody is conjugated to AlphaLISA acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Inquire for Price
Stock for this item is limited, but may be available in a warehouse close to you. Please make sure that you are logged in to the site so that available stock can be displayed. If the call is still displayed and you need assistance, please call us at 1-800-932-5000.
Stock for this item is limited, but may be available in a warehouse close to you. Please make sure that you are logged in to the site so that available stock can be displayed. If the call is still displayed and you need assistance, please call us at 1-800-932-5000.
This product is marked as restricted and can only be purchased by approved Shipping Accounts. If you need further assistance, email VWR Regulatory Department at Regulatory_Affairs@vwr.com
-Additional Documentation May be needed to purchase this item. A VWR representative will contact you if needed.
This product has been blocked by your organization. Please contact your purchasing department for more information.
The original product is no longer available. The replacement shown is available.
This product is no longer available. Alternatives may be available by searching with the VWR Catalog Number listed above. If you need further assistance, please call VWR Customer Service at 1-800-932-5000.
1 - 16 of 35,853
no targeter for Bottom